CN101007792A - Synthesis process of nitro thiazoly benzamide compound - Google Patents
Synthesis process of nitro thiazoly benzamide compound Download PDFInfo
- Publication number
- CN101007792A CN101007792A CN 200710067119 CN200710067119A CN101007792A CN 101007792 A CN101007792 A CN 101007792A CN 200710067119 CN200710067119 CN 200710067119 CN 200710067119 A CN200710067119 A CN 200710067119A CN 101007792 A CN101007792 A CN 101007792A
- Authority
- CN
- China
- Prior art keywords
- stir
- nitrothiazole
- add
- product
- ethyl acetate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种合成硝基噻唑苯酰胺化合物的方法。在丙酮中加入摩尔比为2∶1的乙酰水杨酸和2-氨基-5-硝基噻唑,-2℃~3℃下搅拌。再加入缩合剂DCC(N,N-二环己基碳二亚胺),然后加入三乙胺。-2℃~3℃下搅拌3-6小时。体系过滤,滤液用乙酸乙酯和水萃取,乙酸乙酯层用无水硫酸钠干燥,活性炭脱色。在100~300Pa下减压蒸馏浓缩,浓缩液用异丙醇在-2℃~3℃搅拌,淅晶。得到粗产品,用二氯甲烷重结晶,可得到较纯产品。本发明反应条件温和,操作简单,易于控制。而且反应速度快,反应转化率达到75.3~90.5%,产品收率达到60.5~78.2%,经过重结晶后产品的纯度达到98~99%,且合成全过程所用溶剂都是低毒或无毒,它是一种很有工业前景的合成方法。The invention discloses a method for synthesizing nitrothiazole benzamide compounds. Add acetylsalicylic acid and 2-amino-5-nitrothiazole in a molar ratio of 2:1 into acetone, and stir at -2°C to 3°C. Then add the condensing agent DCC (N, N-dicyclohexylcarbodiimide), and then add triethylamine. Stir at -2°C to 3°C for 3-6 hours. The system was filtered, the filtrate was extracted with ethyl acetate and water, the ethyl acetate layer was dried over anhydrous sodium sulfate, and decolorized with activated carbon. Concentrate by distillation under reduced pressure at 100-300Pa, stir the concentrate with isopropanol at -2°C-3°C, and crystallize. A crude product was obtained, which was recrystallized with dichloromethane to obtain a relatively pure product. The invention has mild reaction conditions, simple operation and easy control. Moreover, the reaction speed is fast, the reaction conversion rate reaches 75.3-90.5%, the product yield reaches 60.5-78.2%, the purity of the product after recrystallization reaches 98-99%, and the solvents used in the whole synthesis process are all low-toxic or non-toxic. It is a synthetic method with great industrial prospects.
Description
技术领域technical field
本发明涉及一种合成o-[N-(5-硝基-2-噻唑基)氨基甲酰基]乙酸苯酯(o-[N-(5-Nitrothiazol-2-yl)carbamoyl]phenyl acetate)的方法。The invention relates to a method for synthesizing o-[N-(5-nitrothiazol-2-yl)carbamoyl]phenyl acetate (o-[N-(5-Nitrothiazol-2-yl)carbamoyl]phenyl acetate) method.
背景技术Background technique
o-[N-(5-硝基-2-噻唑基)氨基甲酰基]乙酸苯酯(o-[N-(5-Nitrothiazol-2-yl)carbamoyl]phenyl acetate)是合成药物硝唑尼特(Nitazoxanide)的原料药,商品名Alinia,它是一种新的抗原虫药,由美国FDA批准其液体制剂治疗隐孢子虫病(Cry-tosporidium parvum)和肠贾第虫(Giardialamblia)所致1~11岁儿童的腹泻。本药物口服吸收快,易于排泄。[陈阜新,韩洪刚,硝唑尼特——种新的抗原虫药,中国药师,2004,7(5),394~395]。o-[N-(5-Nitrothiazol-2-yl)carbamoyl]phenyl acetate is the synthetic drug nitazoxanide (Nitazoxanide) raw material drug, trade name Alinia, it is a new antiprotozoal drug, approved by the U.S. FDA for its liquid preparation to treat cryptosporidiosis (Cry-tosporidium parvum) and intestinal giardia (Giardialamblia) caused by 1 Diarrhea in children up to 11 years old. The drug is rapidly absorbed orally and easily excreted. [Chen Fuxin, Han Honggang, Nitazoxanide—a new antiprotozoal drug, Chinese Pharmacist, 2004, 7(5), 394~395].
关于o-[N-(5-硝基-2-噻唑基)氨基甲酰基]乙酸苯酯的合成,文献报道的合成方法主要有两种。Regarding the synthesis of o-[N-(5-nitro-2-thiazolyl)carbamoyl]phenyl acetate, there are mainly two synthetic methods reported in the literature.
一种方法是以2-氨基5-硝基噻唑和乙酰水杨酸为原料,乙酰水杨酸经酰氯化,再与2-氨基5-硝基噻唑反应合成。[Rossignol,Jean-Francois(FR),Cavier,Raymond(FR).New derivatives of 2-benzamido-5-nitrothiazoles(P),U.S.3950351,April 13,1976],此方法主要缺点是在最后的反应过程中乙酰水杨酸易脱掉其上的乙酰基。反应不易控制。One method is to use 2-amino 5-nitrothiazole and acetylsalicylic acid as raw materials, acetylsalicylic acid is chlorinated, and then reacted with 2-amino 5-nitrothiazole to synthesize. [Rossignol, Jean-Francois (FR), Cavier, Raymond (FR). New derivatives of 2-benzamido-5-nitrothiazoles (P), U.S.3950351, April 13, 1976], the main shortcoming of this method is that in the final reaction process In acetylsalicylic acid, it is easy to remove the acetyl group on it. The reaction is not easy to control.
另一种报道的合成方法是以2-氨基5-硝基噻唑和水杨酸为原料,水杨酸通过酰氯化再与2-氨基5-硝基噻唑反应,反应后所得产物再经乙酸酐乙酰化得到产品[李少华.熊远珍.匡滨海,硝唑尼特合成方法的改进,中国现代应用药学杂志,2006.10,23(5),368~369]。此方法步骤较多,且反应过程中严格要求无水,这就给工业生产带来了不便。Another reported synthetic method is to use 2-amino 5-nitrothiazole and salicylic acid as raw materials, and salicylic acid is reacted with 2-amino 5-nitrothiazole by acyl chloride, and the product obtained after the reaction is subjected to acetic anhydride Acetylation to obtain products [Li Shaohua. Xiong Yuanzhen. Kuang Binhai, Improvement of the synthesis method of nitazoxanide, Chinese Journal of Modern Applied Pharmacy, 2006.10, 23(5), 368-369]. There are many steps in this method, and anhydrous is strictly required in the reaction process, which brings inconvenience to industrial production.
发明内容Contents of the invention
本发明的目的是提供一种合成硝基噻唑苯酰胺化合物(o-[N-(5-Nitrothiazol-2-yl)carbamoyl]phenyl acetate)的合成方法。The object of the present invention is to provide a kind of synthetic method of nitrothiazol benzamide compound (o-[N-(5-Nitrothiazol-2-yl)carbamoyl]phenyl acetate).
本发明采用的技术方案是包括以下步骤:The technical solution adopted in the present invention comprises the following steps:
1)在丙酮中加入摩尔比为2∶1的乙酰水杨酸和2-氨基-5-硝基噻唑,丙酮与乙酰水杨酸的比例为10ml∶10mmol,在-2℃~3℃下搅拌0.5~1小时;1) Add acetylsalicylic acid and 2-amino-5-nitrothiazole in acetone with a molar ratio of 2:1, the ratio of acetone to acetylsalicylic acid is 10ml:10mmol, and stir at -2°C to 3°C 0.5 to 1 hour;
2)再加入与2-氨基-5-硝基噻唑比为3~1∶1的缩合剂DCC,滴加完毕后,然后加入与2-氨基-5-硝基噻唑摩尔比为4∶1的三乙胺;在-2℃~3℃下搅拌3-6小时;2) Then add the condensing agent DCC with a ratio of 3 to 1:1 to 2-amino-5-nitrothiazole. Triethylamine; Stir at -2°C to 3°C for 3-6 hours;
3)步骤2)中反应后混合物用布氏漏斗过滤,滤液在100~300Pa下减压浓缩,得浅黄色油状物,油状物用乙酸乙酯和水萃取,其体积比为10∶1;乙酸乙酯层用无水硫酸钠干燥,活性炭脱色;在100~300Pa下减压蒸馏浓缩,浓缩液用异丙醇在-2℃~3℃搅拌,析结晶;得到粗产品,用二氯甲烷重结晶,可得到纯度为98~99%的产品。其结构式如下:3) The reaction mixture in step 2) is filtered with a Buchner funnel, and the filtrate is concentrated under reduced pressure at 100 to 300 Pa to obtain a light yellow oil, which is extracted with ethyl acetate and water in a volume ratio of 10:1; acetic acid The ethyl ester layer was dried with anhydrous sodium sulfate and decolorized with activated carbon; concentrated by distillation under reduced pressure at 100-300Pa, the concentrated solution was stirred with isopropanol at -2°C to 3°C, and crystallized; the crude product was obtained and reconstituted with dichloromethane Crystallization, a product with a purity of 98-99% can be obtained. Its structural formula is as follows:
本发明具有的有益效果是:反应条件温和,操作简单,易于控制。而且反应速度快,反应转化率达到75.3~90.5%,产品收率达到60.5~78.2%,经过重结晶后产品的纯度达到98~99%,且合成全过程所用溶剂都是低毒或无毒,它是一种很有工业前景的合成方法。The invention has the beneficial effects of mild reaction conditions, simple operation and easy control. Moreover, the reaction speed is fast, the reaction conversion rate reaches 75.3-90.5%, the product yield reaches 60.5-78.2%, the purity of the product after recrystallization reaches 98-99%, and the solvents used in the whole synthesis process are all low-toxic or non-toxic. It is a synthetic method with great industrial prospects.
具体实施方式Detailed ways
下面结合实施例对本发明作进一步说明。The present invention will be further described below in conjunction with embodiment.
实施例1Example 1
将乙酰水杨酸(20mmol,3.62g)和2-氨基-5-硝基噻唑(10mmol,1.45g)加入到10ml丙酮中,-2℃~3℃下,搅拌0.5~1小时,慢慢滴加DCC/丙酮溶液(20mmol/20ml),滴加完毕后开始滴加三乙胺/丙酮溶液(40mol/10ml),再搅拌3~5小时(以上过程均在-2℃~3℃下搅拌进行),反应混合物用布氏漏斗过滤,滤饼用5ml丙酮洗涤.滤液在100~300Pa下减压浓缩至5ml,浓缩液用水和乙酸乙酯萃取,水和乙酸乙酯的量分别为40ml和400ml,乙酸乙酯相用无水硫酸钠干燥,过滤,滤液用1.5g活性碳脱色,趁热过滤,滤液在100~300Pa下减压蒸馏浓缩,浓缩液用20ml异丙醇在-2℃~3℃下搅拌,析结晶,得浅黄色粗产品。粗产品用40ml二氯甲烷重结晶,得纯产品2.35g,产率78.0%。纯度99%。Add acetylsalicylic acid (20mmol, 3.62g) and 2-amino-5-nitrothiazole (10mmol, 1.45g) into 10ml of acetone, stir at -2°C to 3°C for 0.5 to 1 hour, drop slowly Add DCC/acetone solution (20mmol/20ml), after the dropwise addition, start to add triethylamine/acetone solution (40mol/10ml) dropwise, and then stir for 3 to 5 hours (the above process is carried out at -2°C to 3°C) ), the reaction mixture was filtered with a Buchner funnel, and the filter cake was washed with 5ml of acetone. The filtrate was concentrated to 5ml under reduced pressure at 100~300Pa, and the concentrated solution was extracted with water and ethyl acetate. The amount of water and ethyl acetate was 40ml and 400ml respectively , the ethyl acetate phase was dried with anhydrous sodium sulfate, filtered, the filtrate was decolorized with 1.5g of activated carbon, filtered while hot, the filtrate was concentrated by distillation under reduced pressure at 100-300Pa, and the concentrated solution was heated with 20ml of isopropanol at -2°C to 3 Stir at ℃ to crystallize to obtain a pale yellow crude product. The crude product was recrystallized with 40ml of dichloromethane to obtain 2.35g of pure product with a yield of 78.0%. 99% pure.
实施例2Example 2
将乙酰水杨酸(20mmol,3.62g)和2-氨基-5-硝基噻唑(10mmol,1.45g)加入到10ml丙酮中,-2℃~3℃下,搅拌0.5~1小时,慢慢滴加DCC/丙酮溶液(15mmol/20ml),滴加完毕后开始滴加三乙胺/丙酮溶液(40mol/10ml),再搅拌3~5小时(以上过程均在-2℃~3℃下进行),反应混合物用布氏漏斗过滤,滤饼用5ml丙酮洗涤.滤液在100~300Pa下减压浓缩至5ml,浓缩液用水和乙酸乙酯萃取,水和乙酸乙酯的量分别为40ml和400ml,乙酸乙酯相用无水硫酸钠除水,过滤,滤液用1.5g活性碳脱色,趁热过滤,滤液在100~300Pa下减压蒸馏浓缩,浓缩液用20ml异丙醇在-2℃~3℃下搅拌,析结晶,得浅黄色粗产品.粗产品用40ml二氯甲烷重结晶,得纯产品2.20g,产率73.2%。纯度98%。Add acetylsalicylic acid (20mmol, 3.62g) and 2-amino-5-nitrothiazole (10mmol, 1.45g) into 10ml of acetone, stir at -2°C to 3°C for 0.5 to 1 hour, drop slowly Add DCC/acetone solution (15mmol/20ml), after the dropwise addition, start to drop triethylamine/acetone solution (40mol/10ml), and stir for 3 to 5 hours (all the above processes are carried out at -2°C to 3°C) , the reaction mixture was filtered with a Buchner funnel, and the filter cake was washed with 5ml of acetone. The filtrate was concentrated to 5ml under reduced pressure at 100~300Pa, and the concentrated solution was extracted with water and ethyl acetate. The amounts of water and ethyl acetate were 40ml and 400ml respectively, The ethyl acetate phase was dehydrated with anhydrous sodium sulfate, filtered, the filtrate was decolorized with 1.5g of activated carbon, filtered while hot, the filtrate was concentrated by distillation under reduced pressure at 100-300Pa, and the concentrated solution was heated with 20ml of isopropanol at -2°C to 3 Stir at ℃ and crystallize to obtain a pale yellow crude product. The crude product is recrystallized with 40 ml of dichloromethane to obtain 2.20 g of a pure product with a yield of 73.2%. 98% purity.
实施例3Example 3
将乙酰水杨酸(20mmol,3.62g)和2-氨基-5-硝基噻唑(10mmol,1.45g)加入到10ml丙酮中,-2℃~3℃下,搅拌0.5~1小时,慢慢滴加DCC/丙酮溶液(10mmol/20ml),滴加完毕后开始滴加三乙胺/丙酮溶液(40mol/10ml),再搅拌3~5小时(以上过程均在-2℃~3℃下进行),反应混合物用布氏漏斗过滤,滤饼用5ml丙酮洗涤.滤液在100~300Pa下减压浓缩至5ml,浓缩液用水和乙酸乙酯萃取,水和乙酸乙酯的量分别为40ml和400ml,乙酸乙酯相用无水硫酸钠除水,过滤,滤液用1.5g活性碳脱色,趁热过滤,滤液在100~300Pa下减压蒸馏浓缩,浓缩液用20ml异丙醇在-2℃~3℃下搅拌,析结晶,得浅黄色粗产品,粗产品用40ml二氯甲烷重结晶,得纯产品2.0g,产率65.0%。纯度98%。Add acetylsalicylic acid (20mmol, 3.62g) and 2-amino-5-nitrothiazole (10mmol, 1.45g) into 10ml of acetone, stir at -2°C to 3°C for 0.5 to 1 hour, drop slowly Add DCC/acetone solution (10mmol/20ml), after the dropwise addition, start to drop triethylamine/acetone solution (40mol/10ml), and then stir for 3 to 5 hours (all the above processes are carried out at -2°C to 3°C) , the reaction mixture was filtered with a Buchner funnel, and the filter cake was washed with 5ml of acetone. The filtrate was concentrated to 5ml under reduced pressure at 100~300Pa, and the concentrated solution was extracted with water and ethyl acetate. The amount of water and ethyl acetate was 40ml and 400ml respectively, The ethyl acetate phase was dehydrated with anhydrous sodium sulfate, filtered, the filtrate was decolorized with 1.5g activated carbon, filtered while hot, the filtrate was concentrated by distillation under reduced pressure at 100-300Pa, and the concentrated solution was heated with 20ml of isopropanol at -2°C to 3 Stir at ℃, and crystallize to obtain a light yellow crude product, which is recrystallized with 40 ml of dichloromethane to obtain 2.0 g of a pure product, with a yield of 65.0%. 98% purity.
实施例4Example 4
将乙酰水杨酸(20mmol,3.62g)和2-氨基-5-硝基噻唑(10mmol,1.45g)加入到10ml丙酮中,-2℃~3℃下,搅拌0.5~1小时,慢慢滴加DCC/丙酮溶液(30mmol/20ml),滴加完毕后开始滴加三乙胺/丙酮溶液(40mol/10ml),再搅拌3~5小时(以上过程均在-2℃~3℃下进行),反应混合物用布氏漏斗过滤,滤饼用5ml丙酮洗涤.滤液在100~300Pa下减压浓缩至5ml,浓缩液用水和乙酸乙酯萃取,水和乙酸乙酯的量分别为40ml和400ml,乙酸乙酯相用无水硫酸钠除水,过滤,滤液用1.5g活性碳脱色,趁热过滤,滤液在100~300Pa下减压蒸馏浓缩,浓缩液用20ml异丙醇在-2℃~3℃下搅拌,析结晶,得浅黄色粗产品.粗产品用40ml二氯甲烷重结晶,得纯产品2.4g,产率78.2%。纯度99%。Add acetylsalicylic acid (20mmol, 3.62g) and 2-amino-5-nitrothiazole (10mmol, 1.45g) into 10ml of acetone, stir at -2°C to 3°C for 0.5 to 1 hour, drop slowly Add DCC/acetone solution (30mmol/20ml), after the dropwise addition, start to drop triethylamine/acetone solution (40mol/10ml), and stir for 3 to 5 hours (all the above processes are carried out at -2°C to 3°C) , the reaction mixture was filtered with a Buchner funnel, and the filter cake was washed with 5ml of acetone. The filtrate was concentrated to 5ml under reduced pressure at 100~300Pa, and the concentrated solution was extracted with water and ethyl acetate. The amount of water and ethyl acetate was 40ml and 400ml respectively, The ethyl acetate phase was dehydrated with anhydrous sodium sulfate, filtered, the filtrate was decolorized with 1.5g activated carbon, filtered while hot, the filtrate was concentrated by distillation under reduced pressure at 100-300Pa, and the concentrated solution was heated with 20ml of isopropanol at -2°C to 3 Stir at ℃ and crystallize to obtain a light yellow crude product. The crude product is recrystallized with 40 ml of dichloromethane to obtain 2.4 g of a pure product with a yield of 78.2%. 99% pure.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200710067119A CN101007792B (en) | 2007-01-31 | 2007-01-31 | A kind of method for synthesizing nitrothiazole benzamide compound |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200710067119A CN101007792B (en) | 2007-01-31 | 2007-01-31 | A kind of method for synthesizing nitrothiazole benzamide compound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101007792A true CN101007792A (en) | 2007-08-01 |
| CN101007792B CN101007792B (en) | 2010-05-26 |
Family
ID=38696489
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200710067119A Expired - Fee Related CN101007792B (en) | 2007-01-31 | 2007-01-31 | A kind of method for synthesizing nitrothiazole benzamide compound |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101007792B (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101602744B (en) * | 2009-06-30 | 2011-06-01 | 青岛康地恩药业有限公司 | A kind of preparation method of nitazoxanide |
| CN105175352A (en) * | 2015-10-27 | 2015-12-23 | 杭州澳医保灵药业有限公司 | Preparation method of nitazoxanide |
| CN106831640A (en) * | 2015-12-03 | 2017-06-13 | 江苏正大丰海制药有限公司 | A kind of preparation method of Nitazoxanide crystal |
| FR3110164A1 (en) * | 2020-05-15 | 2021-11-19 | Phv Pharma | Process for preparing nitazoxanide and its derivatives and use for the prevention or treatment of pathological conditions due to infection by viruses of the coronavirus type, and more particularly of the SARS-CoV-2 type |
| CN115504941A (en) * | 2021-06-07 | 2022-12-23 | 南京卡文迪许生物工程技术有限公司 | High-purity nitazoxanide synthesis method simple to operate |
| DE112022004799T5 (en) | 2021-10-05 | 2024-08-14 | Council Of Scientific And Industrial Research An Indian Registered Body Incorporated Under The Regn. Of Soc. Act (Act Xxi Of 1860) | Improved process for the preparation of nitazoxanide and intermediates thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1437800A (en) * | 1973-08-08 | 1976-06-03 | Phavic Sprl | Derivatives of 2-benzamido-5-nitro-thiazoles |
-
2007
- 2007-01-31 CN CN200710067119A patent/CN101007792B/en not_active Expired - Fee Related
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101602744B (en) * | 2009-06-30 | 2011-06-01 | 青岛康地恩药业有限公司 | A kind of preparation method of nitazoxanide |
| CN105175352A (en) * | 2015-10-27 | 2015-12-23 | 杭州澳医保灵药业有限公司 | Preparation method of nitazoxanide |
| CN106831640A (en) * | 2015-12-03 | 2017-06-13 | 江苏正大丰海制药有限公司 | A kind of preparation method of Nitazoxanide crystal |
| FR3110164A1 (en) * | 2020-05-15 | 2021-11-19 | Phv Pharma | Process for preparing nitazoxanide and its derivatives and use for the prevention or treatment of pathological conditions due to infection by viruses of the coronavirus type, and more particularly of the SARS-CoV-2 type |
| CN115504941A (en) * | 2021-06-07 | 2022-12-23 | 南京卡文迪许生物工程技术有限公司 | High-purity nitazoxanide synthesis method simple to operate |
| DE112022004799T5 (en) | 2021-10-05 | 2024-08-14 | Council Of Scientific And Industrial Research An Indian Registered Body Incorporated Under The Regn. Of Soc. Act (Act Xxi Of 1860) | Improved process for the preparation of nitazoxanide and intermediates thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101007792B (en) | 2010-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101007792B (en) | A kind of method for synthesizing nitrothiazole benzamide compound | |
| CN101874016B (en) | Manufacturing method of 2-hydroxy-5-phenylalkylaminobenzoic acid derivatives and their salts | |
| CN113214133B (en) | A kind of synthetic method of melatonin | |
| CN103450131B (en) | The preparation method of a kind of dehydroacetic acid (DHA) and sodium salt thereof | |
| CN102317256B (en) | Process for preparing racecadotril | |
| CN101735085B (en) | Method for preparing D-serine by kinetic resolution | |
| CN112142648B (en) | Preparation method of miglitol | |
| CN109553550B (en) | Method for synthesizing dihydrooat alkaloid | |
| CN101180263B (en) | Preparation method of substituted tetrafluorobenzylaniline compound and pharmaceutically acceptable salt thereof | |
| CN102153609B (en) | Chemical synthesis method for 6-methylene monoester | |
| CN115197150B (en) | Preparation method of L-carnosine | |
| CN106542958B (en) | A kind of preparation method of o-iodoaniline | |
| CN108084212B (en) | Preparation method of cefditoren pivoxil | |
| CN113214181A (en) | New preparation method of mosapride | |
| CN105566223A (en) | Crude iminostilbene product recrystallization method | |
| CN117700298A (en) | A kind of preparation method of hydroxyadapalene | |
| WO2019129309A1 (en) | Preparation method for dexamethasone intermediate | |
| CN105330585B (en) | A kind of preparation method of Mitiglinide Calcium | |
| CN107709313B (en) | A kind of method for preparing trityl candesartan | |
| CN108203396B (en) | Synthesis of enkephalinase inhibitor | |
| CN114751818A (en) | Preparation method of azelaic acid alpha crystal form | |
| JPS58172344A (en) | Manufacture of phenylalkanoic acid | |
| CN114539100A (en) | Terbutaline derivative D and preparation method and application thereof | |
| CN101492388A (en) | Method for synthesizing meldonium drug raw material | |
| SU1034605A3 (en) | Process for preparing molecular compound of beta-diethylaminoethylamide of n-chloroacetic phenoxy acid with 4-n-butyl-3,5-diketo-1,2-diphenylpyrazolidine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Fuzhou Sanhe Pharmachem Co., Ltd. Assignor: Zhejiang University Contract record no.: 2011360000080 Denomination of invention: Synthesis process of nitro thiazoly benzamide compound Granted publication date: 20100526 License type: Exclusive License Open date: 20070801 Record date: 20110707 |
|
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100526 Termination date: 20140131 |